TELA Bio, Inc. (NASDAQ:TELA) Insider Ew Healthcare Partners Fund 2, Buys 13,950 Shares


Share on StockTwits

TELA Bio, Inc. (NASDAQ:TELA) insider Ew Healthcare Partners Fund 2, bought 13,950 shares of the firm’s stock in a transaction on Thursday, January 28th. The shares were bought at an average cost of $13.68 per share, for a total transaction of $190,836.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Ew Healthcare Partners Fund 2, also recently made the following trade(s):

  • On Thursday, February 4th, Ew Healthcare Partners Fund 2, purchased 2,822 shares of TELA Bio stock. The shares were acquired at an average price of $14.29 per share, for a total transaction of $40,326.38.
  • On Monday, February 1st, Ew Healthcare Partners Fund 2, purchased 1,119 shares of TELA Bio stock. The shares were acquired at an average price of $14.16 per share, for a total transaction of $15,845.04.
  • On Tuesday, January 26th, Ew Healthcare Partners Fund 2, purchased 1,544 shares of TELA Bio stock. The shares were acquired at an average price of $14.24 per share, for a total transaction of $21,986.56.
  • On Friday, January 15th, Ew Healthcare Partners Fund 2, purchased 763 shares of TELA Bio stock. The shares were acquired at an average price of $13.88 per share, for a total transaction of $10,590.44.
  • On Wednesday, January 13th, Ew Healthcare Partners Fund 2, purchased 7,002 shares of TELA Bio stock. The shares were acquired at an average price of $13.90 per share, for a total transaction of $97,327.80.

TELA stock traded down $0.52 during midday trading on Tuesday, hitting $15.76. The stock had a trading volume of 2,072 shares, compared to its average volume of 24,083. The firm has a market cap of $227.45 million, a P/E ratio of -5.59 and a beta of 2.08. The company has a current ratio of 16.65, a quick ratio of 15.90 and a debt-to-equity ratio of 0.54. TELA Bio, Inc. has a 1-year low of $5.25 and a 1-year high of $23.55. The business has a fifty day moving average price of $14.69 and a two-hundred day moving average price of $15.33.

A number of hedge funds have recently added to or reduced their stakes in the stock. American International Group Inc. lifted its holdings in TELA Bio by 23.5% in the third quarter. American International Group Inc. now owns 4,103 shares of the company’s stock valued at $68,000 after buying an additional 782 shares during the period. California State Teachers Retirement System raised its holdings in shares of TELA Bio by 14.3% during the third quarter. California State Teachers Retirement System now owns 9,361 shares of the company’s stock valued at $155,000 after purchasing an additional 1,173 shares during the period. Opaleye Management Inc. raised its holdings in shares of TELA Bio by 0.8% during the fourth quarter. Opaleye Management Inc. now owns 365,000 shares of the company’s stock valued at $5,490,000 after purchasing an additional 2,926 shares during the period. Bank of America Corp DE raised its holdings in shares of TELA Bio by 398.2% during the second quarter. Bank of America Corp DE now owns 4,334 shares of the company’s stock valued at $56,000 after purchasing an additional 3,464 shares during the period. Finally, State Street Corp raised its holdings in shares of TELA Bio by 6.7% during the third quarter. State Street Corp now owns 65,610 shares of the company’s stock valued at $1,085,000 after purchasing an additional 4,097 shares during the period. Institutional investors and hedge funds own 67.59% of the company’s stock.

Separately, Piper Sandler lifted their price target on shares of TELA Bio from $17.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, November 11th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $19.80.

About TELA Bio

TELA Bio, Inc, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

Featured Story: What does earnings per share mean?

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.